“
“Inferior vena cava (IVC) thrombosis is a complication that occurs in 1-32% of patients inserted with IVC filters (IVCF). Deployment of the filter in the suprarenal position is advocated in certain clinical conditions, and some reports suggest a higher incidence of renal complications in that position, especially among patients with malignancy. We report a case of acute kidney injury (AKI) due to acute thrombosis of a suprarenal IVCF, which was successfully treated

with systemic thrombolytic therapy. We also provide a review of the literature in regard to the indications, complications, and outcomes of suprarenal IVCF. Suprarenal IVCF placement should be performed rarely, and then only after Linsitinib in vitro careful evaluation of the underlying renal function, and likely should be avoided in patients with malignancy and known hypercoagulable state. Systemic thrombolytic therapy is

a feasible treatment option for acute thrombotic episodes of IVCF, assuming it is diagnosed early and there are no known contraindications.”
“Aim: The aim of this study was to assess the usefulness of (153)samarium-ethylene-diamino-tetramethylene phosphonic acid (Sm-153-EDTMP, a beta and gamma emitter) treatment in the palliation of painful bone metastases find more from breast cancer. Patients and Methods: 43 women (aged 41-79, mean 60 years) with bone-disseminated breast cancer and bone pain refractory to opioid analgesics received Sm-153-EDTMP. Karnofsky performance status, pain score (numeric rating scale), analgesic score (World Health Organisation) and blood count were evaluated before treatment and 1 and 3 months after the treatment. Results: Significant pain relief was observed in 51 and 42% of the patients, mild relief in 30 and 30%, and no effect in 19 and 28% of the patients 1 and 3 months after administration, respectively. Mild and transient

bone marrow suppression was observed as a side effect of Sm-153-EDTMP treatment. None of the patients showed grade 4 haematological toxicity and only 1 patient showed grade 3 (National Cancer Institute common toxicity criteria). The majority of patients had grade 1 or 2 haematological toxicity. Conclusion: Sm-153-EDTMP treatment Compound C cost is effective and safe in bone pain palliation in breast cancer. 3 months after administering Sm-153-EDTMP, pain relief to varying degrees was observed in 72% of patients. The haematological toxicity after 153Sm- EDTMP treatment was mild and transient.”
“The extraction yields of anthocyanins (TMA) and total phenolics (TPC) from mangosteen hull were optimized by varying the amplitude and time of ultrasonic treatment. The highest TMA recovery of 2.92 mg cy-3-glu/g hull powder was achieved using methanol aqueous solvent when direct ultrasonic treatment was applied for 15 min at 20% amplitude. For the TPC, 245.78 mg GAE/g hull powder was obtained in ethanol with sonication time of 25 min and at 80% amplitude. These TMA and TPC yields obtained are respectively 45.6% and 8.8% higher (p<0.